This product is a blood suppository containing dextroheparin sodium. Dextroheparin sodium is a low molecular weight heparin sodium derived from the mucosa of pig intestines with an average molecular weight of 5000. Dheparin sodium mainly enhances its inhibition of coagulation factor Xa and thrombin through antithrombin (AT), thus exerting its antithrombotic effect. The ability of this product to enhance the inhibitory effect of coagulation factor Xa was higher than its ability to prolong plasma coagulation time (APTT). This product has less effect on platelet function and platelet adhesion than heparin, so it has only a small effect on hemostasis in the primary stage. Some of the antithrombotic properties of this product are thought to be mediated through the vascular wall or fibrinolytic system.
The acute toxicity of dextroheparin sodium is much lower than that of heparin. The most obvious response repeated in toxicology studies was local bleeding at the injection site after high-dose injection. The incidence and extent of these reactions are dose-related and do not accumulate. The local hemorrhagic response was associated with dose-related changes in anticoagulation and was measured by APTT and anti-xa activity. At the same dose, no stronger osteopenia was observed compared with heparin, which was similar. No organ toxicity was found regardless of the route of administration, dose or treatment cycle. No mutagenic reactions were found. Fetal toxicity and teratogenic effects during pregnancy and effects on fertility, perinatal or postpartum were not found.